Traditional Korean medicine treatment for tamoxifen associated adverse events of breast cancer patient: A CARE – Compliant case report

Jung, 2019, Prediction of cancer incidence and mortality in Korea, Cancer Res Treat, 51, 431, 10.4143/crt.2019.139 van Hellemond, 2018, Current status of extended adjuvant endocrine therapy in early stage breast cancer, Curr. Treat. Options Oncol., 19, 26, 10.1007/s11864-018-0541-1 Davies, 2011, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 378, 771, 10.1016/S0140-6736(11)60993-8 Hadji, 2010, Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy, Crit. Rev. Oncol. Hematol., 73, 156, 10.1016/j.critrevonc.2009.02.001 Condorelli, 2018, Managing side effects in adjuvant endocrine therapy for breast cancer, Expert Rev. Anticancer Ther., 18, 1101, 10.1080/14737140.2018.1520096 Qi, 2015, The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer, Biosci Trends, 9, 16, 10.5582/bst.2015.01019 Kuo, 2018, Use of complementary traditional Chinese medicines by adult cancer patients in taiwan: a nationwide population-based study, Integr. Canc. Ther., 17, 531, 10.1177/1534735417716302 Wang, 2015, Effects of traditional Chinese medicine in treatment of breast cancer patients after mastectomy: a meta-analysis, Cell Biochem. Biophys., 71, 1299, 10.1007/s12013-014-0348-z Hershman, 2018, Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial, J. Am. Med. Assoc., 320, 167, 10.1001/jama.2018.8907 Chien, 2017, Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis, PloS One, 12, 10.1371/journal.pone.0180918 Tsai, 2014, The use of Chinese herbal products and its influence on tamoxifen induced endometrial cancer risk among female breast cancer patients: a population-based study, J. Ethnopharmacol., 15, 1256, 10.1016/j.jep.2014.07.008 Riley, 2017, CARE guidelines for case reports: explanation and elaboration document, J. Clin. Epidemiol., 89, 218, 10.1016/j.jclinepi.2017.04.026 World Health Organization WHO Blumel, 2018, Decision-making for the treatment of climacteric symptoms using the Menopause Rating Scale, Maturitas, 111, 15, 10.1016/j.maturitas.2018.02.010 Shin, 2012, Measurement of quality of life in menopausal women: a systematic review, West. J. Nurs. Res., 34, 475, 10.1177/0193945911402848 Jordan, 1995, Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer, Annu. Rev. Pharmacol. Toxicol., 35, 195, 10.1146/annurev.pa.35.040195.001211 Marino, 2016, How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer?, Menopause, 23, 1000, 10.1097/GME.0000000000000664 Heinemann, 2004, The Menopause Rating Scale (MRS) scale: a methodological review, Health Qual. Life Outcome, 2, 45, 10.1186/1477-7525-2-45 Schneider, 2000, The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints, Climacteric, 3, 59, 10.3109/13697130009167600 Dolye, 2018, Validation of the MENQOL for use with women who have been treated for gynecologic or breast cancer, Can. Oncol. Nurs. J., 28, 228 Hilditch, 1996, A menopause-specific quality of life questionnaire: development and psychometric properties, Maturitas, 24, 161, 10.1016/0378-5122(96)01038-9 Heinemann, 2004, The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study, Health Qual. Life Outcome, 2, 67, 10.1186/1477-7525-2-67 Constantine, 2019, Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms, Menopause, 26, 513, 10.1097/GME.0000000000001261 Lee, 2016, Quantitative evaluation of Oryeongsan and its action on water regulation in renal inner medullary collecting duct cells, J. Ethnopharmacol., 185, 310, 10.1016/j.jep.2016.03.030 Lee Jc, 2013, Two cases of cancer-induced lymphedema patients treated with oryeongsan, Korean J Orient Int Med, 34, 322 Yue, 2019, Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer, Phytomedicine, 56, 103, 10.1016/j.phymed.2018.10.003 Cheng, 2019, Characteristics of the traditional Liu-Wei-Di-Huang prescription reassessed in modern pharmacology, Chin. J. Nat. Med., 17, 103, 10.1186/s13020-022-00658-9 Nizamutdinova, 2008, Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells, Int. J. Oncol., 33, 485 Gong, 2012, Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of aurora A expression and function, PloS One, 7, 10.1371/journal.pone.0033656 Chen, 2012, The in vivo therapeutic effect of free wanderer powder (逍 遙 散 xiāo yáo sǎn, Xiaoyaosan) on mice with 4T1 cell induced breast cancer model, J Tradit Complement Med, 2, 67, 10.1016/S2225-4110(16)30073-6 Greenlee, 2017, Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment, CA Cancer J Clin, 67, 194, 10.3322/caac.21397 Cai, 2018, Brain functional connectivity network studies of acupuncture: a systematic review on resting-state fMRI, J Integr Med, 16, 26, 10.1016/j.joim.2017.12.002 Bae, 2015, Acupuncture for aromatase inhibitor–induced arthralgia: a systematic review, Integr. Canc. Ther., 14, 496, 10.1177/1534735415596573 Chen, 2013, In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab, Menopause, 20, 646, 10.1097/gme.0b013e31827b2240 Chang, 2006, Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of HER-2 signaling, Menopause, 13, 967, 10.1097/01.gme.0000227025.96686.8b Chiu, 2014, Screening to identify commonly used Chinese herbs that affect ERBB2 and ESR1 gene expression using the human breast cancer MCF-7 cell line, Evid Based Complement Alternat Med, 965486 Yue, 2019, Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer, Phytomedicine, 56, 103, 10.1016/j.phymed.2018.10.003 Kim, 2015, Treaditional herbal medicine as adjuctive therapy for breast cancer: a systematic review, Compl. Ther. Med., 23, 626, 10.1016/j.ctim.2015.03.011